The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients

Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations

(2018) Matthew Dankner et al.   ONCOGENE

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib

(2017) Chao-Chi Ho et al.   Journal of Thoracic Oncology

Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

(2017) David Planchard et al.   LANCET ONCOLOGY

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS

(2017) Zhan Yao et al.   NATURE

AACR Project GENIE: Powering Precision Medicine through an International Consortium

(2017)   Cancer Discovery

Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer andBRAFmutation

(2017) Xi Ding et al.   Cancer Medicine

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

(2016) Fabrice Barlesi et al.   LANCET

Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

(2016) David Planchard et al.   LANCET ONCOLOGY

Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

(2016) David Planchard et al.   LANCET ONCOLOGY

Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations

(2016) Claire Tissot et al.   LUNG CANCER

Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool

(2015) Jamal Carter et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

(2015) David M. Hyman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prevalence and clinical significance of BRAF V600E in Chinese patients with lung adenocarcinoma

(2015) Zhenxiang Li et al.   Thoracic Cancer

Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer

(2015) Monika Joshi et al.   PLoS One

Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma

(2015) Ling Shan et al.   PLoS One

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboringBRAFmutations in the Lung Cancer Mutation Consortium

(2014) Liza C. Villaruz et al.   CANCER

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

(2014) Mark G. Kris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features

(2014) Yunjian Pan et al.   LUNG CANCER

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non-Small Cell Lung Cancer

(2013) S. Cardarella et al.   CLINICAL CANCER RESEARCH

Comprehensive genomic characterization of squamous cell lung cancers

(2012)   NATURE

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations

(2011) Antonio Marchetti et al.   JOURNAL OF CLINICAL ONCOLOGY